AMRN—I have no strong opinion one way or the other on whether Vascepa will get NCE status (and that’s what I’ve said all along). The document you referenced doesn’t add anything probative to the discussion, IMO.
The reason you probably thought I was negative on NCE status is that I’ve said I don’t expect AMRN’s patents to stand up to Paragraph-IV challenges, which can come soon if NCE status is not granted. Regards, Dew
Market Data 
Markets 
AI
